Company news
Travere Therapeutics, Inc. (NASDAQ:TVTX) news
Travere Therapeutics, Inc. news releases on 6ix. Latest, Jan 6, 2025: Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Press releases — page 2
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Travere Therapeutics to Present at Upcoming Investor Conferences
November 24, 2024
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 11, 2024
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 6, 2024
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 6, 2024
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 30, 2024
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 25, 2024
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 20, 2024
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 16, 2024
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
October 16, 2024
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 13, 2024
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 25, 2024
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 9, 2024
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 4, 2024
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 21, 2024
Travere Therapeutics Reports Second Quarter 2024 Financial Results
July 31, 2024
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 24, 2024
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 7, 2024
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 8, 2024
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 5, 2024
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 28, 2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 23, 2024
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 23, 2024
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 3, 2024
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 2, 2024
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 10, 2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 22, 2024
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
February 22, 2024
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 24, 2024
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 7, 2024
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 13, 2023
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
December 3, 2023
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
Travere Therapeutics Reports Third Quarter 2023 Financial Results
November 6, 2023
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 2, 2023
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 23, 2023
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 12, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
September 25, 2023
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 20, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2023
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 4, 2023
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 30, 2023
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 23, 2023
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 2, 2023
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 19, 2023
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 16, 2023